Sugi Predict

Sugi Predict / Compounds / SCHEMBL1042866

SCHEMBL1042866

SCHEMBL1042866

C[C@H](CO)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H3 Q13133 7/20 1.00
▸ OSBP P22059 6/20 1.00
▸ RORC P51449 5/20 1.00
▸ GRIN1 Q05586 6/20 0.84
▸ GRIN2A Q12879 6/20 0.84
▸ OSBP2 Q969R2 3/20 0.84
▸ USP2 O75604 1/20 0.84
▸ LMNA P02545 1/20 0.84
▸ ABCB1 P08183 1/20 0.84
▸ CYP46A1 Q9Y6A2 1/20 0.84
▸ DHCR24 Q15392 1/20 0.80
▸ CRYAB P02511 1/20 0.76
▸ HMGCR P04035 1/20 0.76
▸ ITGB3 P05106 1/20 0.76
▸ ITGAV P06756 1/20 0.76
▸ SREBF2 Q12772 1/20 0.76
▸ NPC1L1 Q9UHC9 1/20 0.76
▸ GRIN2B Q13224 5/20 0.75
▸ EPHA2 P29317 1/20 0.72
▸ NR1H2 P55055 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6391967 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL288494 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL159618 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL23960515 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL13076858 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL24937893 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL1176969 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL22095720 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL22559557 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A
SCHEMBL288733 1.00 NR1H3 (1.00) NR1H3OSBPRORCGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025081338-A1 MODULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR FOR TREATMENT OF INFECTIONS WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2025-04-24 — — WO claimed
CN-119269811-A Neuroactive steroids, compositions, and uses thereof 萨奇治疗股份有限公司 2025-01-07 — — CN claimed
CN-111386338-B Method for producing a cell mass comprising cells of the nervous system or a nervous tissue and a non-neuroepithelial tissue, and cell mass 住友化学株式会社 2024-10-08 — — CN claimed
CN-117015400-A Treatment of diseases associated with ATP-binding cassette transporter 1 dysfunction using TREM2 agonists 维吉尔神经科学股份有限公司 2023-11-07 — — CN claimed
CN-116964454-A Treatment of diseases associated with colony stimulating factor 1 receptor dysfunction using TREM2 agonists 维吉尔神经科学股份有限公司 2023-10-27 — — CN claimed
CN-116322710-A Pharmaceutical composition comprising gamma-cyclodextrin polymer and use thereof 株式会社雷纳图斯 2023-06-23 — — CN claimed
EP-3852757-A1 CH24H INHIBITORS FOR PAIN USE Takeda Pharmaceutical Company Limited (JP) 2021-07-28 — — EP claimed
WO-2020059894-A1 CH24H Inhibitors For Pain Use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-03-26 — — WO claimed
WO-2019176857-A1 PROMOTER FOR INDUCING DIFFERENTIATION OF INSULIN-PRODUCING CELLS 味の素株式会社 2019-09-19 — — WO claimed
CN-108713025-A Slave single carrier for treating the heart patient's condition and other pathology expresses the composition and method of multiple biological activities polypeptide 英特拉克森公司 2018-10-26 — — CN claimed
CN-105164161-A Neuroactive steroids, compositions, and uses thereof SAGE THERAPEUTICS INC 2015-12-16 — — CN claimed
CN-105018509-A Mutant receptors and their use in a nuclear receptor-based inducible gene expression system RHEOGENE INC 2015-11-04 — — CN claimed
CN-102776218-A Mutant receptors and their use in a nuclear receptor-based inducible gene expression system INTREXON CORP 2012-11-14 — — CN claimed
CN-1434865-A Regulation of the binding box transporter ABC1 CV THERAPEUTICS INC (US) 2003-08-06 — — CN claimed
US-20260124157-A1 METHODS OF SELF-AMPLIFYING RNA-LIPID NANOPARTICLE MANUFACTURE AND COMPOSITIONS DERIVED THEREFROM GENVAX TECH INC (US) 2026-05-07 — — US disclosed
US-20260034178-A1 METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE, AND CELL MASS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2026-02-05 — — US disclosed
EP-4659812-A1 DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION Bumm, Thomas (DE) 2025-12-10 — — EP disclosed
EP-0946584-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 1999-10-06 — — EP disclosed
WO-1999047136-A1 PREVENTION AND TREATMENT OF ADHESIONS NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 1999-09-23 — — WO disclosed
WO-1998028323-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 1998-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034178-A1 METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE, AND CELL MASS THEREOF BMP1, BMP4, SHH NR1H3 3624/4885OSBP 2789/4885RORC 1423/4885
US-20260124157-A1 METHODS OF SELF-AMPLIFYING RNA-LIPID NANOPARTICLE MANUFACTURE AND COMPOSITIONS DERIVED THEREFROM HNRNPM, SARNP, SNRPF NR1H3 707/4885OSBP 732/4885RORC 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.